TLR2 and rheumatoid arthritis: Another approach to inhibiting TLR function in RA is by neutralising antibodies (biologicals); Opsona Therapeutics (Dublin, Ireland) have developed a TLR2 neutralising antibody which they have shown can reduce spontaneous cytokine production from RA synovial explants [37].